BeyondSpring, Inc. · NASDAQ:BYSI
BeyondSpring — Investor Presentation (September 2023)
40 slides from BeyondSpring's investor presentation, September 2023
Slide 1: September 2023 | NASDAQ: BYSI
September 2023 | NASDAQ: BYSI
Slide 2: Disclaimer
Disclaimer This presentation has been prepared for informational purposes only. No money or other consideration is being solicited, and if sent in response, will not be accepted. This presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shal
Slide 3: Investment Highlights
Investment Highlights Plinabulin: Safety Lead Asset Plinabulin: >700 cancer patients treated with good & Efficacy tolerability; Positive Phase 3 data in 2 indications Plinabulin Plinabulin: Dual Benefit in anti-cancer and prevention of CIN; Potential Potential in re-sensitizing in PD-1/PD-L1 progres
Slide 4: Pipeline
Pipeline Indication/Target Program Preclinical Phase 1 Phase 2 Phase 3 Registration Trial Name / Collaborator NSCLC Plinabulin + Docetaxel DUBLIN-3 Late stage (2nd/3rd line) Plinabulin + PROTECTIVE-1 CIN Prevention Pegfilgrastim & PROTECTIVE-2 SCLC Plinabulin + PD-1 + (2nd/3rd line) CTLA-4 Investiga
Slide 5: Plinabulin: Induce Innate and Adaptive Immunity
Plinabulin: Induce Innate and Adaptive Immunity By depolymerizing microtubules, plinabulin releases, or activates, immune-defense protein GEF-H1. This leads to dendritic cell maturation (the most potent APC). In WT DC cells, plinabulin can induce DC maturation, but not in GEF-H1 deleted DC cells2 Pl
Slide 6: Plinabulin Franchise
Plinabulin Franchise Clinical Confirmation Expand Transform Promising early clinical efficacy data Positive topline Phase 3 OS data Confirmed in 6 clinical studies & NDA Review in China CIN NSCLC Multiple Cancers (I/O Combo) 6
Slide 7: SEED Therapeutics: Target Protein Degradation (TPD) Company
SEED Therapeutics: Target Protein Degradation (TPD) Company 7
Slide 8: SEED Therapeutics
SEED Therapeutics Founders: • Avram Hershko, MD PhD (Nobel Prize Winner, Technion), a world expert in ubiquitin-mediated TPD research; • Ning Zheng, PhD (HHMI, Pharmacology Dept, University of Washington), a pioneer in structural biology of ubiquitin E3 ligases; • Michele Pagano, MD (HHMI, Chairman,
Slide 9: TPD Targets 80% of Disease-Causing Proteins That Are Currently Undruggable
Targeted Protein Degradation (TPD) Targets 80% of Disease-Causing Proteins That are Currently Undruggable Druggable Proteins TPD for Undruggable Proteins https://doi.org/10.1124/mol.117.111062 9
Slide 10: Nature Derived TPD Molecular Glue Approved To Degrade Cancer-causing Proteins
Nature Derived TPD Molecular Glue Approved To Degrade Cancer- causing Proteins Normal cell protein regulation via proteasomal degradation • Natural method for selective protein degradation • Nature derived IMIDs are approved molecular glues that hijack E3 ligases to degrade cancer causing proteins S
Slide 11: Strong Scientific Foundation With Proven Execution Capability
Strong Scientific Foundation With Proven Execution Capability to Timely Deliver Drug Pipeline for Multiple Unmet Medical Needs World-Leading Scientific Expertise → Translate to Drug Pipeline Avram Hershko Ning Zheng, Michele James Tonra, Lan Huang, PhD MD, PhD PhD Pagano, MD PhD Pioneer in the Pione
Slide 12: Exceeding Seed Financing Expectations
Exceeding Seed Financing Expectations SEED Internal Program Milestones Translation of SEED Platforms into Drug Development of SEED’s unique TPD platforms and filed Infrastructure and Organization Pipeline of 7 disclosed programs in patents Building various disease areas • Multi-dimensional platforms
Slide 13: How SEED Differentiates Itself in Surmounting Challenges
How SEED Differentiates Itself in Surmounting Challenges Unique How to identify the right E3 for protein of interest (POI)? Challenges Target-Centric Identify the right E3 for POI to increase the success rate in drug Differentiation discovery: Platforms using Quasi-degron, LumID, and Basal Affinity
Slide 14: SEED's Multi-dimensional, Proprietary Platform for E3 Selection
SEED’s Multi-dimensional, Proprietary Platform for E3 Selection Knowledge-based Direct Binding Validation LumID: Identify the right E3 in the Quasi Degron Approach “living cell” near protein of interest B B E3 B Target Neo Target Neo Target 1 Quasi Degron B Weakened Binding I L I L E3 C A A E3 A E3
Slide 15: 7 Drug R&D Pipeline in Multiple Disease Areas
7 Drug R&D Pipeline in Multiple Disease Areas Target Protein Target Molecular Indication / Target E3 Ligase ID Lead ID IND Candidate IND Filing Initiative* Selection Glue HTS Target Alpha NeuroD Tau Project X 1st IND 2024 KRAS-G12D Cancer Target Beta FEN1 Antiviral HBx * 6 of 7 Targets Unpartnered 1
Slide 16: Project X: Lead ST-00973 Expected to Enter IND in 2024
Project X: Lead ST-00973 Expected to Enter IND in 2024 POC: Degradation of Target protein Superb In Vivo Efficacy: Good In Vivo Safety: in Cell Complete Tumor Regression No Weight Loss 6h 24h 1000 35 Tumor Volume(mm3) 800 Body Weight (g) 30 600 Target Protein 25 400 200 20 Vinculin 0 15 0 3 6 9 12 0
Slide 17: SEED (TPD 2.0) - Differentiated among High-value TPD Companies
SEED (TPD 2.0) - Differentiated among High-value TPD Companies Molecular Glue/Monovalent Pharma Companies Licensing Deals in E3:Target Protein TPD Assets Basal Interaction Discovery: Basal LumID • Deal Size Affinity • Upfront: $40 - $415 M Sold to Bayer for Quasi-Interface 1.5 B upfront • Milestone:
Slide 18: Summary: First to Market and Best in Class
Summary: First to Market and Best in Class 1. Target-centric SEED Breakthrough TPD Platforms Employ Multi-dimensional Proprietary Platforms for E3 Selection • 80% of disease-causing proteins are undruggable, presenting a tremendous medical opportunity for SEED’s new drug development platform; • With
Slide 19: Plinabulin: Chemotherapy-Induced Neutropenia (CIN) Prevention Indication
Plinabulin: Chemotherapy-Induced Neutropenia (CIN) Prevention Indication 19
Slide 20: CIN: Unmet Medical Need in Low White Blood Cell Count
CIN: Unmet Medical Need in Low White Blood Cell Count (depth of Neutropenia) in Week 1 After Chemotherapy Despite widespread G-CSF use, CIN is #1 reason for FN, ER visits, hospitalization, sepsis, mortality, and chemotherapy dose reduction and disruption1 Short-term Long-term G-CSF can reduce the du
Slide 21: Six Clinical Studies Confirm Plinabulin's Neutropenia Prevention Benefit
Six Clinical Studies Confirm Plinabulin’s Neutropenia Prevention Benefit Plinabulin enables more use of chemotherapy ANC-based Benefit Clinical Benefit Study 101 (Phase 2) Grade 3/4 Neutropenia (C1D8): Sepsis: 0% Plinabulin vs. 3.6% Placebo - Docetaxel, NSCLC Plinabulin (n=90, 10% G-CSF): 7% vs. Sev
Slide 22: PROTECTIVE-2 (106 Study, Phase 2): Rationale for the Combination
PROTECTIVE-2 (106 Study, Phase 2): Rationale for the Combination ANC in Cycle 1 After TAC for Breast Cancer - Pegfilgrastim Unmet need in ANC protection in Week 1 - Plinabulin fills the Gap Pegfilgrastim vs Plinabulin Plinabulin + Pegfilgrastim vs Pegfilgrastim 7 Pegfilgrastim (6.0 mg) (n=22) Pegfil
Slide 23: Met Primary Endpoint in PROTECTIVE-2 (106 Study) Phase 2
Met Primary Endpoint in PROTECTIVE-2 (106 Study) Phase 3 Design: Double blind, global study (19 centers); 4 cycles Plinabulin 40 mg + Pegfilgrastim 6 mg N=111 Breast Cancer, R TAC Therapy 1:1 Placebo + Pegfilgrastim 6 mg N=110 Results: Proportion of Patients with NO Grade 4 Neutropenia (or DSN= 0 Da
Slide 24: Superior Improvement Seen with the Combination Compared to Pegfilgrastim Alone
106 Phase 3: Superior Improvement Seen with the Combination in Clinically Meaningful Endpoints Compared to Pegfilgrastim Alone Reduction of Incidence and Reduction of Profound Severity of FN and Neutropenia (PN) Related Hospitalization Benefits Plinabulin improves depth of neutropenia Clinical Endpo
Slide 25: Potential for Use Across the Spectrum of Solid Tumors
Potential for Use Across the Spectrum of Solid Tumors G-CSF Administrations: Across Solid Tumor Gynecologic Rectal al Cancer, Cancer Other 5% Plinabulin Differentiated Benefit for Ovarian Cancer 5% CIN Prevention compared with G-CSF 5% • Improve depth of neutropenia; Prostate Cancer 6% Female • Firs
Slide 26: 2nd/3rd Line NSCLC Indication
2nd/3rd Line NSCLC Indication 26
Slide 27: 2L/3L NSCLC, no Driver Mutation: Docetaxel as Standard of Care
2L/3L NSCLC, no Driver Mutation: Docetaxel as Standard of Care (SOC) With PD-1/PD-L1 moving to 1L, Docetaxel remains SOC for 2L/3L NSCLC Pemetrexed and PD-1/PD-L1 Moved To First Line Ramuciramab + Docetaxel vs. Treatment Pemetrexed vs Docetaxel2 Nivolumab (PD-1 Ab) vs. Docetaxel3 Docetaxel1 Limited
Slide 28: DUBLIN-3 (Study 103) Trial Design
DUBLIN-3 (Study 103) Trial Design Docetaxel + Plinabulin vs. Docetaxel + Placebo in Patients with EGFR Wild-Type NSCLC End Points: Primary Endpoint: OS Secondary Endpoints: Study Plan: • ORR, PFS • Global, randomized, single-blinded (patients only) • Percent of patients without severe neutropenia on
Slide 29: Met Primary Endpoint of OS; Significantly Improve 2-, 3-year OS Rate
Met Primary Endpoint of OS; Significantly Improve 2-, 3-year OS Rate 100 Docetaxel Docetaxel+ plinabulin Docetaxel Docetaxel + placebo Censored + Plinabulin (DP) + Placebo (D) 80 Survival Probability (%) DP (n=278) D (n=281) Events, n(%) 214 (77.0) 230 (81.9) 60 Median overall survival 10.5 9.4 43.4
Slide 30: Significant Reduction in Grade 4 Neutropenia
Significant Reduction in Grade 4 Neutropenia Cycle 1 Day 8 and All Cycles Day 8 Grade 4 neutropenia, Cycle 1 Day 8 Grade 4 neutropenia, All Cycles Day 8 50% 50% P<0.0001 P<0.0001 40% 40% Percentage of Patients Percentage of Patients 33.58% 30% 27.80% 30% 20% 20% 10% 10% 5.26% 5.13% 0% 0% Docetaxel +
Slide 31: Significant Improvement in Quality of Life Benefit
Anti- Significant Improvement in Quality of Life Benefit Cancer - Q-TWiST (Quality-Adjusted Time Without Symptoms of Disease and Toxicity) Plinabulin + Docetaxel Twist alone Clinically Meaningful Improvement of >18% in Q-TWiST. 31
Slide 32: Potential Benefit of Plinabulin + Docetaxel in 2L/3L NSCLC
Potential Benefit of Plinabulin + Docetaxel in 2L/3L NSCLC, No Driver Mutation With PD-1/PD-L1 moving to 1st line NSCLC, plinabulin + docetaxel could be the potential choice. Benefits compared to SOC Docetaxel: Efficacy: • Significant survival benefit in ITT (OS HR=0.82), with more pronounced surviv
Slide 33: Immuno-Oncology Combinations
Immuno-Oncology Combinations 33
Slide 34: Mechanism with Broad Applications
Mechanism with Broad Applications Plinabulin Induces Dendritic Cell Maturation (the most potent APC), a Key Step in Initiating Anti-Cancer Durable Response ❷ Plinabulin ❸ Checkpoint Inhibitors Hit the Gas Release The Brakes Stimulates maturation of dendritic Optimize T cell response cells to increas
Slide 35: Clinical POC in Triple Plinabulin IO Combination Regimen
Clinical POC in Triple Plinabulin IO Combination Regimen Indication / Program Preclinical Phase 1 Phase 2 Phase 3 Collaborator Target 7 cancers Plinabulin + PD-1/PD-L1 + (PD-1/PD-L1 Radiation progressed) NSCLC (2L/3L, PD-1/PD-L1 Plinabulin + PD-1 + Docetaxel progressed) MD Anderson Phase 1 study cli
Slide 36: Plinabulin as Potential Add-on Therapy to Current I/O Regimens
Plinabulin as Potential Add-on Therapy to Current I/O Regimens to Address Severe Unmet Medical Needs PD-1/PD-L1 Inhibitors Potential to greatly expand the - $30B global annual sales addressable market Current Severe Unmet Medical Needs Plinabulin Clinical Development Re-sensitize: Plinabulin + PD-1/
Slide 37: Regulatory Pathway
np BeyondSpring Regulatory Pathway
Slide 38: Regulatory Pathway
Regulatory Pathway Near-Term Long-Term CIN: Ongoing discussion with Seek regulatory clarity and NMPA in China and FDA in the additional approvals in countries US; around the world. NSCLC: Ongoing preparation to file for NDA approval in China and the US. 38
Slide 39: Investment Highlights
Investment Highlights Plinabulin: Safety Lead Asset Plinabulin: >700 cancer patients treated with good & Efficacy tolerability; Positive Phase 3 data in 2 indications Plinabulin Plinabulin: Dual Benefit in anti-cancer and prevention of CIN; Potential Potential in re-sensitizing in PD-1/PD-L1 progres
Slide 40: www.beyondspringpharma.com
www.beyondspringpharma.com 40
BeyondSpring — Investor Presentation (September 2023) on 6ix